Live, 24 - 25 September 2020

Schedule

Create your personal agenda –check the favourite icon

Sep 2408:55
Conference pass
Sep 2409:00
Conference pass

Innovation in industry and practical considerations for biotechs

Keynotes
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Sep 2409:20
Conference pass

Trends in modelling approaches for successful reimbursement of ATMPs

Keynotes
Ion Agirrezabal, Senior Consultant, Covance Market Access And Phase Iv Solutions, Covance Market Access
Sep 2409:40
Conference pass

Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value

Keynotes
Bharat Tewarie, Executive Vice President And Chief Marketing Officer, UCB
Sep 2410:00
Conference pass

Around the world in 80 MEAs

Keynotes
Ezequiel Heredia, Consultant, Lifescience Dynamics Ltd
Sep 2411:20
Conference pass

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Keynotes
Sep 2411:40
Conference pass

Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

Keynotes
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Sep 2412:00
Conference pass

Roundtables

Keynotes
Roundtable 10: Accelerating access to treatments for rare diseases
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Roundtable 11: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter, Partner, Viopas Partners
Roundtable 12: Exploring reimbursement and healthcare systems across the Middle East
Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie
Roundtable 13: Access and HTA considerations for Russia and CIS countries
Nabil Seidov, Deputy Head Of Department For Health Policy And Planning Of Public Health And Reforms Centre, Ministry of Healthcare of Azerbaijan Republic
Roundtable 14: Indication based pricing- where are we?
David Catterick, Head Of Market Access Uk, Amgen
Roundtable 15: Access and HTA considerations for Turkey, Kazakhstan and Ukraine
Oleksandr Topachevskyi, Essential Medicines List Committee Member, Ministry of Health of Ukraine
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Kagan Atikeler, Researcher, Utrecht University
Roundtable 16: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster, Head Market Access, Santhera Pharmaceuticals
Roundtable 17: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay, Chief Operating Officer, Wits Health Consortium
Roundtable 18: Exploring innovative reimbursement and payment models for orphan drugs
Sebastian Soluch, Head Of Market Access And Pricing, Europe, Stemline Therapeutics Inc
Roundtable 19: Branded combo-pricing: Where to next?
Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer
Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie
Roundtable 20:Achieving greater collaboration with HTAs: Insights from EUnetHTA & Industry
Francesca Cook, Senior Director, Global Head Of Pricing And Market Access, Regenxbio
Roundtable 21: Developments in pricing and patient access for speciality treatments
Keith White, Vice President And Head, Global Market Access, Corbus Pharmaceuticals
Jenny Ebert, National Account Director, Ascendis Pharma
Roundtable 22: Virtual approaches for real-world research
Roundtable 23: Pricing Strategy – What to Do and When?
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Roundtable 24: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan, Global Market Access - Health Systems Strategy, Value Recognition, Roche
Roundtable 25: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
Roundtable 26: Game-changing policies for game-changing innovations: what regulatory changes to ensure the development, diffusion and sustainability of new technologies
Gerard De Pouvourville, Professor And Chairman, Health Economics And Management, ESSEC Business School
Julien Patris, Associate Director Of Market Access And Policy For Europe And Canada, Alnylam
Roundtable 27: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich, Managing Director, Plich Advisory
Roundtable 28: Exploring access and pricing challenges for low to middle income countries
Giovanny Leon, P&Ma Director, Novartis AG
Marijn Verhoef, Engagement Manager, Access to Medicine Foundation
Roundtable 29: Access and pricing considerations for CAR-T development
Nuno Prego Ramos, Chief Executive Officer, CellmAbs
Roundtable 2: How do you include the patient perspective in a outcomes-based contract?
Girisha Fernando, CEO, Lyfegen HealthTech AG
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Roundtable 30: Exploring commercial strategies for orphan drugs in the public healthcare system of Argentina
Marcelo Sal, Head of Market Access and Pricing, Argentina, PTC Therapeutics
Roundtable 31: Challenges associated with communicating the value of Cell & Gene Therapies
Anushini Muthutantri, Director, Evidence, Value And Access, Consulting at McCann Health
Jasim Uddin, Head of Evidence, Value & Access, Consulting at McCann Health
Roundtable 32: HTA developments across Eastern Europe
Tatyana Benisheva, Professor In Drug Regulatory Affairs, Bulgarian Association For Drug Information
Roundtable 33: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther, General Manager, EVERSANA
Roundtable 34: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Roundtable 35: Patient based generated evidence
David Elvira, Heads Eu Public Affairs, Sanofi
Roundtable 36: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Jost Leemhuis, Head Of Safety Science, Roche
Irina Odnoletkova, Vice President Health Technology Assessment, Apogenix Gmbh
Roundtable 37: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Roundtable 3: Capability building for RWE
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Sandra Paci, Director Market Access Europe, Argenx
Roundtable 4: Payer insights and engagement for BeneLux
Diane Kleinermans, Advisor To The Ministry Of Health And Social Affairs, Belgian Federal Government
Bart Vermeulen, Deputy Director Healthcare At Office Of The Minister Of Social Affairs And Public Health, Belgian Federal Government
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, NIHDI - INAMI Belgium
Roundtable 5: HTA insights and engagement for Italy
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Roundtable 6: A tale of two diseases: how orphan drugs can navigate NICE
Josie Godfrey, Director, JG Zebra Consulting
Roundtable 7: Achieving positive reimbursement negotiations
Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh
Roundtable 8: The development of a patient advocate – How to find experienced and qualified patient advocates- The Continual Professional Development approach
Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement
Roundtable 9: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Sep 2414:10
Conference pass

Chair’s remarks

EVIDENCE
Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie
Sep 2414:10
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Sep 2414:10
Conference pass

Chair’s remarks

RARE DISEASES
Nicki Catterick, Senior Director, Global Market Access And Pricing, Merck Group
Sep 2414:10
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Sep 2414:10
Conference pass

Chair’s remarks

HTA
Reg Waldeck, Oncology Market Access Strategy Leader, Bayer Corp
Sep 2414:10
Conference pass

Chair’s remarks

THE FAR EAST
Mark Chalmers, Director, Navigant – A Guidehouse Company
Sep 2414:15
Conference pass

Can Pharma save $1 billion through the strategic use of RWE?

EVIDENCE
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Sep 2414:15
Conference pass

Lessons learnt in implementing an outcomes based contract

PRICING & MARKET ACCESS
Diar Fattah, Global Director, Innovative Value Strategies And Evidence (Respiratory), AstraZeneca
Sep 2414:15
Conference pass

Patient access to rare disease treatments: Insights from industry

RARE DISEASES
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Sep 2414:15
Conference pass

Big data & AI in pricing and access to medicines

BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Sep 2414:15
Conference pass

Horizon scanning in the HTA process; helping to facilitate UK market access

HTA
Dapo Ogunbayo, Programme Manager - Healthcare Innovations (Pharmaceuticals), NIHR Innovation Observatory, Newcastle University
Sep 2414:15
Conference pass

Market access conditions and healthcare for the Far East and Australasia

THE FAR EAST
Diane Munch, Vice President, Global Pricing, Patient And Health Impact, Pfizer
Samuel Taylor, Emerging Markets Pricing Lead, Pfizer
Sep 2414:15
Conference pass

Delivering Value Effectively: A German perspective

VALUE
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Sep 2414:35
Conference pass

RWE for regulatory and HTA decision-making: latest precedent and what's ahead

EVIDENCE
Ashley Jaksa, VP Analytic Solutions, Aetion, Inc.
Sep 2414:35
Conference pass

Outcome-Based contracts and other innovative pricing models: Expectation or reality?

PRICING & MARKET ACCESS
Sep 2414:35
Conference pass

Patient Access: Challenges for Rare Diseases

RARE DISEASES
Alison Kneen, SVP & Head of DRG Abacus, Decision Resources Group
Sep 2414:35
Conference pass

Optimal Global Pricing: Resolving with exact numerical solutions two problems - Optimal Launch Pricing and Parallel Trade

BIG DATA, DIGITAL HEALTH & ANALYTICS
Mitch Scurtu, President, Global Technologies
Sep 2414:35
Conference pass

EUnetHTA Joint Assessments and Implications for the Industry

HTA
Sep 2414:35
Conference pass

Breaking down the ‘Great Wall’: do the evolving market access policy dynamics in China represent the next big opportunity of Pharma?

THE FAR EAST
Amy Wang, Managing Consultant, Navigant – A Guidehouse Company
Sep 2414:35
Conference pass

Embracing competition to deliver the true value of biosimilars

VALUE
Isabell Remus, Head Biopharmaceuticals Europe, Sandoz
Sep 2414:55
Conference pass

Effective RWE strategy for regulatory approval and reimbursement

EVIDENCE
Nneka Onwudiwe, Founder And Chief Executive Officer, Pharmaceutical Economics Consultants of America (PECA) LLC
Sep 2414:55
Conference pass

Value-based Contracting Status and Outlook

PRICING & MARKET ACCESS
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Sep 2414:55
Conference pass

The continuing changing landscape in creating value beyond price for rare disease products in the US

RARE DISEASES
Diann Potestio, Vice President Market Access, Ascendis Pharma
Sep 2414:55
Conference pass

Diabetes care in the world of digital health: What does the evidence suggest?

BIG DATA, DIGITAL HEALTH & ANALYTICS
Sep 2414:55
Conference pass

The use of frameworks to support HTA processes

HTA
Gwilym Thompson, Director, Markets, Health Economics And Outcomes Research, Bristol-Myers Squibb
Sep 2414:55
Conference pass

Bringing accessibility and affordability to scale in the next decade

THE FAR EAST
Marijn Verhoef, Engagement Manager, Access to Medicine Foundation
Sep 2414:55
Conference pass

Value considerations in Canada’s new regulatory pricing framework

VALUE
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
Sep 2415:15
Conference pass

Chair’s remarks

EMERGING MARKETS
Kevin Loth, Former Vice President, Corporate Affairs And Policy, Worldwide Markets, Celgene
Sep 2415:15
Conference pass

Chair’s remarks

EVIDENCE
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Sep 2415:15
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Sep 2415:15
Conference pass
Sep 2415:15
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Sandro Cesaro-Tadic, Head Pricing I8 And Product Pricing Strategies, Roche
Sep 2415:15
Conference pass

Chair’s remarks

HTA
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Sep 2415:15
Conference pass

Chair’s remarks

VALUE
Gavin Lewis, Vice President For Value, Access And Policy, Amgen
Sep 2415:20
Conference pass

Challenges for reimbursement and innovation in Latin America

EMERGING MARKETS
Giovanny Leon, P&Ma Director, Novartis AG
Sep 2415:20
Conference pass

Living with and Beyond Cancer: The Missing Evidence

EVIDENCE
Richard Stephens, Patient Advocate, Independant
Sep 2415:20
Conference pass

Market access for gene therapies in Germany

PRICING & MARKET ACCESS
Axel Boehnke, Director Market Access Eu North, PTC Therapeutics
Sep 2415:20
Conference pass

Developing advanced therapies for rare diseases: is this sustainable?

RARE DISEASES
Diego Ardigo, R&D Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Sep 2415:20
Conference pass

From Digital To Big Data Analytics & AI In Real World Data

BIG DATA, DIGITAL HEALTH & ANALYTICS
Igor Rudychev, Head Of Us Digital, Data, And Innovations, AstraZeneca
Sep 2415:20
Conference pass
Sep 2415:20
Conference pass

Engaging with the patient to achieve greater value

VALUE
Timothy Lenehan, Senior Director - Global Value And Access, Biogen
Sep 2415:40
Conference pass

Exploring commercial strategies in orphan drugs in the public healthcare system in Argentina

EMERGING MARKETS
Marcelo Sal, Head of Market Access and Pricing, Argentina, PTC Therapeutics
Sep 2415:40
Conference pass

Future Trends - How Payers in the US and Europe are adapting to the ATMP revolution

PRICING & MARKET ACCESS
Herve Lilliu, Chief Executive Officer, inbeeo
Sep 2415:40
Conference pass

Innovative reimbursement and payment models for orphan drugs

RARE DISEASES
Jaime Espin, Professor, Andalusian School Of Public Health
Sep 2415:40
Conference pass

Access and pricing considerations in the world of innovative diagnostics

BIG DATA, DIGITAL HEALTH & ANALYTICS
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Sep 2415:40
Conference pass

Engaging with HTA in Ukraine

HTA
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Sep 2415:40
Conference pass

Understanding the patient’s perspective when assessing value

VALUE
Rebecca Walker, Director, Global Access Strategy, UCB Pharma
Sep 2416:00
Conference pass

The link between HTA and decision-making in resource allocation

EMERGING MARKETS
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Sep 2416:00
Conference pass

Latest developments in evidence for oncology

EVIDENCE
Reg Waldeck, Oncology Market Access Strategy Leader, Bayer Corp
Sep 2416:00
Conference pass

Adopting a patient centric approach to access for gene therapies

PRICING & MARKET ACCESS
Nanxin (Nick) Li, Senior Director and Head, Health Economics and Outcomes Research (HEOR), uniQure
Sep 2416:00
Conference pass

Joint assessment for orphan drugs: Insight from EUnetHTA

RARE DISEASES
Anne Willemsen, Project Manager Eunethta, Zorginstituut Nederland / EUnetHTA
Sep 2416:00
Conference pass

How transparency in R&D can improve access conditions?

BIG DATA, DIGITAL HEALTH & ANALYTICS
Jaume Vidal, Policy Advisor, Eu Projects, Health Action International
Sep 2416:00
Conference pass

The DIVE framework: how to incorporate all information into your estimation process: Direct evidence, Indirect evidence, validation and external information incorporation?

HTA
Mario Ouwens, Senior Statistical Science Director, Astra Zeneca
Sep 2416:00
Conference pass

How do traditional drugs deliver value in the world of gene therapies

VALUE
Juan Roman, Head Of Market Access And Pricing, Acceleron Pharmaceuticals, Inc.
Sep 2416:50
Conference pass

Chair’s remarks

PAYER ENGAGEMENT & STRATEGY
Kart Veliste, Chief Specialist At Department Of Medicines And Medical Devices, Haigekassa Estonia
Sep 2416:50
Conference pass

Chair’s remarks

EMERGING MARKETS
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, Head Of Pricing And Access Capabilities, Emerging Marke, GlaxoSmithKline
Sep 2416:50
Conference pass

Chair’s remarks

GOVERNMENTAL AFFAIRS
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Sep 2416:50
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Cristina Martin-Rinconada, Head Of Value And Access For International Partners Markets (Mena And Ceer Regions), Biogen
Sep 2416:50
Conference pass

Chair’s remarks

RARE DISEASES
Josie Godfrey, Director, JG Zebra Consulting
Sep 2416:50
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Vitaly Doban, Executive Director, Head Of Applied And Advanced Analytics (Rwe, Medical), Novartis
Sep 2416:55
Conference pass

Market access and pricing conditions across the Middle East and Africa

EMERGING MARKETS
Ayman Semaan, Market Access, Algorithm
Sep 2416:55
Conference pass

New developments in Poland for pricing & reimbursement

GOVERNMENTAL AFFAIRS
Marcin Czech, Former Vice Minister, Ministry of Health Poland
Sep 2416:55
Conference pass

Should a large payer like AXA transform its role from prevention and care coordination to healthcare delivery

PAYER ENGAGEMENT & STRATEGY
Charles De Cidrac, Director Of Health Insurance, AXA
Sep 2416:55
Conference pass

Patient engagement in preparation for HTA submissions and acceptance of data

EVIDENCE
Stefan Holmstrom, Head, Hta Strategy And Pro Excellence, Astellas Pharma
Sep 2416:55
Conference pass

The Swedish market: Supporting regional payers in managed introduction and prioritisation of new drug therapies

PRICING & MARKET ACCESS
Sep 2416:55
Conference pass

Looking at the role of patient advocacy in pricing policies

RARE DISEASES
Francois Houyez, Treatment Information And Access Director, Health Policy Advisor, EURORDIS
Sep 2416:55
Conference pass

Digital Medicines: Where are we now and what next

BIG DATA, DIGITAL HEALTH & ANALYTICS
Oliver Gassner, Head G4A Digital Health Intelligence Emea, Bayer
Sep 2417:15
Conference pass

Governmental policy in the healthcare industry across the Middle East

GOVERNMENTAL AFFAIRS
Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie
Sep 2417:15
Conference pass

Pharmaceutical Pricing Policy and Access in South Africa, A Funder’s Perspective – Key Focus on Rare Diseases

EMERGING MARKETS
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Noluthando Nematswerani, Head - Centre For Clinical Excellence, Discovery Health
Sep 2417:15
Conference pass

Understanding the payer assessment process in Norway

PAYER ENGAGEMENT & STRATEGY
Einar Andreassen, Senior Adviser, Hta And Reimbursement, Norwegian Medicines Agency
Sep 2417:15
Conference pass

Developments in Canadian Pharmaceutical Pricing and Market Access

PRICING & MARKET ACCESS
Sep 2417:15
Conference pass

The patient’s journey for neurological diseases

RARE DISEASES
Lara Pippo, Head Of Market Access, CSL Behring
Sep 2417:35
Conference pass

The Sanofi Espoir Foundation- improving access in Africa

EMERGING MARKETS
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi
Sep 2417:35
Conference pass

What is the value of the patient’s perspective when negotiating with payers?

PAYER ENGAGEMENT & STRATEGY
Andrea Mantovani, Former Market Access Executive, Independent
Sep 2417:35
Conference pass

Working with the government in Brazil to encourage innovation in access and the impact across Latin America

GOVERNMENTAL AFFAIRS
Marcela Junqueira, Oncology Market Access DIrector - Latin America, Janssen Pharmaceutical
Sep 2417:35
Conference pass

Looking at the evidence after launch: addressing access hurdles across different markets

EVIDENCE
Rasmus Jensen, Global Head Of Market Access, Camurus
Sep 2417:35
Conference pass

Market access developments for Russia

PRICING & MARKET ACCESS
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Valentin Dodonov, Deputy General Head Of Market Access, BIOCAD
Sep 2417:35
Conference pass

The Hercules Project: Patient-led Access in Rare Diseases

RARE DISEASES
Josie Godfrey, Director, JG Zebra Consulting
Sep 2417:35
Conference pass

Creating an evidence strategy from the perspective of a digital therapeutic start-up

BIG DATA, DIGITAL HEALTH & ANALYTICS
Sven Jungmann, Co-Founder, FoundersLane

Create your personal agenda –check the favourite icon

Sep 2508:55
Conference pass

Chair’s opening remarks

Keynotes
Sarah Pitluck, Head, Global Pricing And Reimbursement, Spark Therapeutics
Sep 2509:00
Conference pass

Market Access considerations from NICE

Keynotes
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Sep 2509:20
Conference pass

Trends in HTA Decisions for Oncology, Single & Combination Therapies

Keynotes
Alan Crowther, General Manager, EVERSANA
Magdi Stino, Product Manager, EVERSANA
Sep 2509:40
Conference pass

Achieving greater stakeholder engagement and innovation to improve outcomes

Keynotes
  • What key initiatives are helping to improve cooperation among payers, patients and manufacturers?
  • What innovation is taking place in contracting?
  • What suggestions would you offer to streamline contracting arrangements and improve patient & payer outcomes?
Sarah Pitluck, Head, Global Pricing And Reimbursement, Spark Therapeutics
Ulf Staginnus, Senior Vice President, Head Of Global Market Access And Pricing, Ipsen Pharma
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Tamir Singer, Head Of Commercial Development, Specialised Commissioning, NHS England
Evert Jan Van Lente, Director Eu-Affairs, AOK Bundesverdand
Sep 2511:00
Conference pass

Roundtables

Keynotes
Roundtable 10: Real world data and its utility in HTA decisions
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Roundtable 11: Market Access and pricing considerations for Spain
Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre
Igor Beitia Ortiz De Zárate, Director Market Access Southern Europe Region, PTC Therapeutics
Jonathan Galduf, Market Access Manager, Sun Pharmaceutical Industries Limited
Roundtable 12: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan, Head - Health Technology Assessment, Discovery Health
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Roundtable 13: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell, Director Market Access UK, Shionogi
Roundtable 14: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.
Roundtable 15: Reserved for Lifescience Dynamics
Roundtable 16: Opportunities & Challenges for Collection of RWD in Early Access Programs (EAPs)
Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health
Roundtable 17: Exploring repurposed products for rare diseases
Amer Omar, Senior Director, Lupin
Roundtable 18: Industry and patients working together for better access
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Roundtable 19: Modelling the value of digital health innovations
Trishal Boodhna, Senior Health Economist, Consulting at McCann Health
Calum Jones, Senior Consultant - Evidence, Value And Access (Heor), Consulting at McCann Health
Roundtable 20: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther, General Manager, EVERSANA
Roundtable 21: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Roundtable 22: Pricing developments in the US and the wider impact
Nicki Catterick, Senior Director, Global Market Access And Pricing, Merck Group
Roundtable 23: Understanding Business Challenges of Shifting IV drugs to SC to Enable Self-delivery
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Alfred Harvey, Associate Director, Health Economics And Outcomes Research, Becton Dickinson
Roundtable 24: Innovative pricing of rare disease medicines – what is pharma’s model for the 2020s
Simon Shohet, Head Of International Market Access, Amicus Therapeutics
Roundtable 25: Exploring value-added medicines
Maja Sercic, Policy&Science Manager, Medicines for Europe
Roundtable 3: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert, Advisor, Independent
Roundtable 4: Accelerating Access to treatments for Rare Diseases
Rob De With, Head of Rare Diseases for Europe and Canada, Takeda
Roundtable 5: How to establish a market access department from scratch?
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Roundtable 6: Evidence solutions and CAR-T
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceutical
Roundtable 7: Exploring the international reference pricing landscape
Tanya Aiden, Global Products Lead, BIOCAD
Roundtable 8: Achieving better alignment amongst stakeholders regarding definitions and concepts of value in diagnostics
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Roundtable 9: Market access, Pricing, Payer & HTA developments for the Nordic Region
Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark
Einar Andreassen, Senior Adviser, Hta And Reimbursement, Norwegian Medicines Agency
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Dorthe Bartels, Strategic Adviser, Amgros
Roundtables 1: Innovation in Contracting
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Roundtables 2: Risk-sharing arrangements: Are they improving patient access to new medicines?
Catarina Lopes Pereira, Global Market Access Manager, Medac
Sep 2512:00
Conference pass

Chair’s remarks

AFFORDABILITY
Simon Shohet, Head Of International Market Access, Amicus Therapeutics
Sep 2512:00
Conference pass

Chair’s remarks

ADVANCED THERAPIES
Omar Dabbous, Vice President, Health Economics And Outcomes Research, AveXis
Sep 2512:00
Conference pass

Chair’s remarks

MANAGED ENTRY AGREEMENTS
Andrea Mantovani, Former Market Access Executive, Independent
Sep 2512:00
Conference pass

Chair’s remarks

EVIDENCE
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Sep 2512:00
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Sep 2512:00
Conference pass

Chair’s remarks

RARE DISEASES
Ines Alves, President, ANDO Portugal
Sep 2512:05
Conference pass

Experiences from managed entry agreements

MANAGED ENTRY AGREEMENTS
Bart Van Den Daele, Head Of External Affairs - Director Market Access, Gilead Sciences
Sep 2512:05
Conference pass

Political factors when considering affordability

AFFORDABILITY
Sep 2512:05
Conference pass

Understanding the advanced therapy landscape and beyond: an investors perspective

ADVANCED THERAPIES
Michael Schroter, Partner, Viopas Partners
Sep 2512:05
Conference pass

Exploring the world of digital healthcare and how we can improve outcomes in RWE and market access

EVIDENCE
Hans Hofstraat, Vice President, Philips Research
Sep 2512:05
Conference pass

Governance in the world of access and pricing

PRICING & MARKET ACCESS
Claudia Neuber, Head Of Global Pricing Implementation, AstraZeneca
Sep 2512:05
Conference pass

Innovation in treating rare diseases: HTA approach in Scotland

RARE DISEASES
Mark Macgregor, Medical Director, Golden Jubilee National Hospital
Sep 2512:25
Conference pass

Cross indication pricing considerations for gene therapy

ADVANCED THERAPIES
Alex Grosvenor, Vice President, Global Pricing and Market Access, Precision Xtract
Sep 2512:25
Conference pass

Political dimensions affecting affordability in the Dutch market

AFFORDABILITY
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Sep 2512:25
Conference pass

Value Evidence Generation in Product Lifecycle Management of Medical Technologies: Fit for Purpose, Fit for Future?

EVIDENCE
Luqman Tariq, Market Access Director, Europe, Stryker Corp
Sep 2512:25
Conference pass

Exploring the international reference pricing landscape

PRICING & MARKET ACCESS
Tanya Aiden, Global Products Lead, BIOCAD
Sep 2512:25
Conference pass

Early Access to treatment for Rare Disease patients

RARE DISEASES
Rob De With, Head of Rare Diseases for Europe and Canada, Takeda
Sep 2512:45
Conference pass

Risk sharing agreements for cell and gene therapies

ADVANCED THERAPIES
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Sep 2512:45
Conference pass

Solving the Affordability Challenge – what pharma companies can do beyond philanthropy

AFFORDABILITY
John Alter, Vice President Pricing And Market Access, Pfizer
Sep 2512:45
Conference pass

What to watch out for in implementing managing entry agreements

MANAGED ENTRY AGREEMENTS
Shanthy Krishnaraja, Senior Director, Market Access And Strategy, Seqirus
Sep 2512:45
Conference pass

Use of reimbursement data for research with respect to GDPR

EVIDENCE
Gottfried Endel, Ebm, Hta Team Leader, Austrian Social Insurance
Sep 2512:45
Conference pass

US insights: Alternative payment methodologies

PRICING & MARKET ACCESS
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Sep 2512:45
Conference pass

Exploring repurposed products for rare diseases

RARE DISEASES
Amer Omar, Senior Director, Lupin
Sep 2514:05
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Sep 2514:05
Conference pass

Chair’s remarks

ADVANCED THERAPIES
Adam Heathfield, Senior Director Of Global Health And Value Innovation Centre, Pfizer Ltd
Sep 2514:05
Conference pass

Chair’s remarks

EVIDENCE
Ramon Hernandez Vecino, Head Of Real World Evidence Data And Analytics Engagement Lead Randd, Sanofi
Sep 2514:05
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Anne Marciniak, Head Of Market Access, Europe, Aimmune
Sep 2514:05
Conference pass

Chair’s remarks

RARE DISEASES
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Sep 2514:10
Conference pass

Achieving Sustainability in Biosimilars

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Sep 2514:10
Conference pass

Experiences from a payer point of view: insights from Denmark

MANAGED ENTRY AGREEMENTS
Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark
Sep 2514:10
Conference pass

How to evaluate and value gene therapies

ADVANCED THERAPIES
Omar Dabbous, Vice President, Health Economics And Outcomes Research, AveXis
Sep 2514:10
Conference pass

Capability-building for SMEs: Starting from Scratch

EVIDENCE
Alexander Bastian, Vice President Of Value And Market Access, Galapagos
Sep 2514:10
Conference pass

Exploring challenges and opportunities across South Africa on achieving new affordable strategies for Universal Health Coverage

PRICING & MARKET ACCESS
Sagie Pillay, Chief Operating Officer, Wits Health Consortium
Sep 2514:10
Conference pass

The incentives’ review by the EU Commission and its implication on OMPs

RARE DISEASES
Ana Palma, Senior Director Global Hta And Patient Access Lead, Sobi
Sep 2514:30
Conference pass

Achieving the best outcomes when negotiating managed entry agreements

MANAGED ENTRY AGREEMENTS
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.
Sep 2514:30
Conference pass

Perspectives from the Alliance for Regenerative Medicine: improving access to cell and gene therapies

ADVANCED THERAPIES
Sep 2514:30
Conference pass

The long-term sustainability of Biosimilars

BIOSIMILARS
Olga Diachenko, Market Access Manager Europe, Accord Healthcare
Sep 2514:30
Conference pass

Developing capabilities to support effective evaluation of data

EVIDENCE
Sue Naeyaert, Advisor, Independent
Sep 2514:30
Conference pass

Achieving greater collaboration with HTAs: Insights from EUnetHTA

PRICING & MARKET ACCESS
Marcus Guardian, Chief Operating Officer, EUnetHTA
Sep 2514:30
Conference pass

New HTA - regulations for Orphan drugs in Germany

RARE DISEASES
Antje Behring, Acting Head, Federal Joint Committee
Sep 2514:50
Conference pass

A look at legislation for Biosimilars in Germany

BIOSIMILARS
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Sep 2514:50
Conference pass

Looking at Value for Advanced Therapies in Quebec

ADVANCED THERAPIES
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Sep 2514:50
Conference pass

The patient perspective in managed entry agreements

MANAGED ENTRY AGREEMENTS
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.
Sep 2514:50
Conference pass

Capability-building in the development of orphan drugs

EVIDENCE
Martine Zimmermann, Global Head Of Regulatory Affairs, Alexion Pharmaceuticals
Sep 2514:50
Conference pass

Market access for Germany with single arm studies

PRICING & MARKET ACCESS
Jorg Tomeczkowski, Head Of Market Access, Janssen Cilag Germany
Sep 2514:50
Conference pass

Where do we go from here - bridging the gap from regulatory approval to market access using MoCA

RARE DISEASES
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Sep 2515:40
Conference pass

Chair’s remarks

CONTRACTING AND PRICE TENDERING
Diar Fattah, Global Director, Innovative Value Strategies And Evidence (Respiratory), AstraZeneca
Sep 2515:40
Conference pass

Chair’s remarks

ADVANCED THERAPIES
Steven Flostrand, Senior Director Of Pricing And Market Access, Celgene, a BMS subsidiary
Sep 2515:40
Conference pass

Chair’s remarks

PATIENT ADOVACY
Steve Sandor, Vice President, Market Access And Trade, Paratek Pharmaceuticals , Inc.
Sep 2515:40
Conference pass

Chair’s remarks

EVIDENCE
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Sep 2515:40
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Hanadi Nahas, Chairman And General Manager, Access Core
Sep 2515:40
Conference pass

Chair’s remarks

RARE DISEASES
Sheela Upadhyaya, Associate Director Hst, National Institute for Health and Care Excellence
Sep 2515:45
Conference pass

Contracting in Germany

CONTRACTING AND PRICE TENDERING
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Sep 2515:45
Conference pass

Reimbursement for gene therapies

ADVANCED THERAPIES
Stefan Vegter, Market Access Manager, Novartis
Sep 2515:45
Conference pass

The importance of patient advocacy for Market Access

PATIENT ADOVACY
Steve Sandor, Vice President, Market Access And Trade, Paratek Pharmaceuticals , Inc.
Sep 2515:45
Conference pass

Real-world evidence and the 2020 NICE Methods Update

EVIDENCE
Micah Rose, Senior Scientific Adviser - Health Economic Modelling, NICE Scientific Advice
Sep 2515:45
Conference pass

Drivers of preference for prefilled syringes for anaesthesia/ICU drugs in British, French and German hospitals

PRICING & MARKET ACCESS
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Sep 2515:45
Conference pass

Working with stakeholders to improve access to rare disease treatments

RARE DISEASES
Natasa Zibelnik, Global Head Of Market Access, EUSA Pharma
Sep 2516:05
Conference pass

Developments in CAR-T and latest regulatory requirements

ADVANCED THERAPIES
Detlev Parow, Head Pharmaceutical Department, D.A.K.
Sep 2516:05
Conference pass

Industry and patients working together for better access

PATIENT ADOVACY
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Sep 2516:05
Conference pass

Use of RWE in clinical trials and improving outcomes

EVIDENCE
Lotte Steuten, Vice President And Head Of Consulting, Office of Health Economics
Sep 2516:05
Conference pass

Latest developments in biomarkers

PRICING & MARKET ACCESS
Irina Odnoletkova, Vice President Health Technology Assessment, Apogenix Gmbh
Sep 2516:25
Conference pass

Access and Pricing considerations for CAR-T

ADVANCED THERAPIES
Nuno Prego Ramos, Chief Executive Officer, CellmAbs
Sep 2516:25
Conference pass

Innovative contracting and payment models for cell and gene therapies

CONTRACTING AND PRICE TENDERING
Ramesh Arjunji, Senior Director Heor And Rwe, AveXis
Sep 2516:25
Conference pass

The value provided to pharma through patient advocacy – hard lessons learnt from industry

PATIENT ADOVACY
Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement
Sep 2516:25
Conference pass

Registries for orphan drugs in the German AMNOG process

EVIDENCE
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Sep 2516:25
Conference pass

Latest insights on patient support programmes across the Middle East

PRICING & MARKET ACCESS
Hanadi Nahas, Chairman And General Manager, Access Core
Sep 2516:25
Conference pass

Bridging the Gap between Payers, Patients & the Advocates Navigating Access to Care

RARE DISEASES
Elizabeth Johnson, Biologics Coordinator, Allergy Partners, P.A.
last published: 06/Jul/20 12:55 GMT

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com